The study was aimed to evaluate the effects of two standard doses of rivaroxaban and
dabigatran on global hemostatic assays in patients with atrial fibrillation. The study included …

Introduction Several specific assays are commercially available to determine dabigatran
anticoagulant activity. Aims of this multicenter and multiplatform study were to compare five …

Background Issues with laboratory measurement of dabigatran include: 1. Do coagulation
assays reflect dabigatran plasma concentrations? 2. Do samples from patients treated with …

Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …

Objectives: To study dabigatran etexilate, a new oral anticoagulant that functions as a direct
thrombin inhibitor. Methods: This study evaluates four methods, one of which is performed in …

Objectives: The goal of this study was to analyze the impact of dabigatran plasma
concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic …

Background: A recommendation for dosage adjustment of dabigatran etexilate, a prodrug of
dabigatran, seems to be desirable based on creatinine clearance to avoid bleeding and …

The dabigatran dose–response is predictable; however, it is necessary to measure plasma
levels in a variety of clinical conditions. We evaluated a novel dabigatran measure–the …

Introduction Warfarin and dabigatran are used to prevent thromboembolism in patients with
atrial fibrillation (AF). Although these medications can effectively prevent ischemic stroke …

Background and Purpose Accurate and rapid assessment of coagulation status is necessary
to guide thrombolysis or reversal of anticoagulation in stroke patients, but commercially …